InflaRx (NASDAQ:IFRX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 418.64% from the stock’s current price.
InflaRx Trading Up 0.2 %
NASDAQ:IFRX traded up $0.00 on Wednesday, hitting $1.54. The company had a trading volume of 34,852 shares, compared to its average volume of 166,307. The stock has a market capitalization of $90.82 million, a price-to-earnings ratio of -1.99 and a beta of 1.57. The firm has a 50 day moving average of $1.49 and a two-hundred day moving average of $1.50. InflaRx has a 52 week low of $1.14 and a 52 week high of $3.08.
InflaRx (NASDAQ:IFRX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.04 million. InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. As a group, equities analysts forecast that InflaRx will post -0.98 EPS for the current year.
Hedge Funds Weigh In On InflaRx
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Read More
- Five stocks we like better than InflaRx
- Upcoming IPO Stock Lockup Period, Explained
- Analyst Think There’s Still Time to Get in on Edgewise, Up 332%
- Investing in Travel Stocks Benefits
- 3 Stocks Raising Dividends 4X Higher Than Inflation
- What Are Some of the Best Large-Cap Stocks to Buy?
- Palantir Stock Joins the S&P 500; Is It Time to Buy?
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.